Welcome to OncLive On Air®! I’m your host today, Megan Hollasch.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Michael Feigin, PhD, about the benzodiazepines lorazepam (Ativan) and alprazolam (Xanax) and their varying impacts on progression-free survival (PFS) outcomes for patients with pancreatic cancer.
Dr Feigin is an associate professor of pharmacology and therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo, New York.
Data from a retrospective study conducted by Dr Feigin’s laboratory at Roswell Park Comprehensive Cancer Center and published in Clinical Cancer Research demonstrated that 40 patients with pancreatic cancer who received lorazepam experienced significantly worse PFS outcomes compared with those who did not receive the agent, with an HR of 3.83 (95% CI, 1.53-9.57). However, 27 patients given alprazolam achieved significantly improved PFS outcomes vs those who had not received the agent with a HR of 0.38 (95% CI, 0.16-0.92).
In our exclusive interview, Dr Feigin discussed methods for conducting this research, data from the study examining mouse models and the tumor microenvironment, and the implications of findings showing that lorazepam activated GPR68 on cancer-associated fibroblasts and led to the production of interleukin 6 (IL-6), while alprazolam potently decreased IL-6 levels.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.